Consensus IDEXX Laboratories, Inc.

Stocks

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 01:30:00 15/08/2026 am IST			5-day change	1st Jan Change
550.96 ^USD	-2.82%		-6.09%	-18.56%

11/08	IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment	MT
11/08	Idexx Laboratories Launches Catalyst Probnp Test for Cardiac Assessment in Cats and Dogs	CI

Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

0acc66e84c.ycOPBoyQ5W2F1_VqzdllDwPQJSz_6qYM5d_1QNpfPjg.ua_cb8i90gLQlY0cpagseFPoTniSruJGtbGzIr03B1mqmvdI26mGGr3ukg~2fde2d5daab73ab6fedaeb1e990663b3

Analysts' recommendations: IDEXX Laboratories, Inc.

11/08	Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating	MT
05/08	Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792	MT
05/08	Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650	MT
05/08	UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating	MT
27/07	Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says	MT
27/07	UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating	MT
13/07	Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating	MT
06/05	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655	MT
06/05	Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785	MT
28/04	UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating	MT
27/04	Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating	MT
15/04	Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target	MT
14/04	Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating	MT
31/03	Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating	MT
09/02	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating	MT
05/02	Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating	MT
05/02	Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850	MT
03/02	Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830	MT
03/02	UBS Adjusts IDEXX Laboratories PT to $730 From $750	MT
03/02	Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785	MT
03/02	BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830	MT
03/02	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700	MT
09/12	Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target	MT
10/11	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700	MT
04/11	UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

550.96USD

Average target price

698.92USD

Spread / Average Target

+26.86%

High Price Target

805.00USD

Spread / Highest target

+46.11%

Low Price Target

470.00USD

Spread / Lowest Target

-14.69%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
Jefferies & Co.
Citigroup
UBS
Leerink Partners
Rothschild & Co Redburn
Stifel Nicolaus
Piper Sandler
BTIG
Morgan Stanley
JPMorgan Chase
BNP Paribas Exane
BofA Securities
Redburn Atlantic
Goldman Sachs
Atlantic Equities
Credit Suisse
Guggenheim
J.P. Morgan Chase